Blog RSS

Analyzing Early Events in TB and TB/HIV Infection for Interventional Targets (R01 - Clinical Trial Not Allowed) expires 10/12/2023

staatsc — Mon, 22 May 2023 14:47:26 +0000

Analyzing Early Events in TB and TB/HIV Infection for Interventional Targets (R01 - Clinical Trial Not Allowed) expires 10/12/2023 staatsc Mon, 05/22/2023 - 09:47 RSS:

Due Dates: October 11, 2023

Open Date: Earliest Submission Date: September 11, 2023

The purpose of this Notice of Funding Opportunity (NOFO) is to support mechanistic studies of the early stage of Mycobacterium tuberculosis (Mtb) infection, with and without HIV, to identify interventional targets for vaccine and host-directed therapies. This Notice of Funding Opportunity (NOFO) will support mechanistic studies of early Mtb infection (defined as the time between Mtb exposure and early-stage granuloma formation) in the airway and lung with the ultimate goal of understanding these events in the setting of HIV co-infection.

More information here

Tags

NIH, NIAID, TB, HIV/AIDS, R01

Lockdown Auth

Peer Reviewed Medical Research Program (PRMRP)

staatsc — Thu, 02 Mar 2023 21:32:39 +0000

Peer Reviewed Medical Research Program (PRMRP) staatsc Thu, 03/02/2023 - 15:32 RSS:

The Peer Reviewed Medical Research Program (PRMRP), established in fiscal year 1999 (FY99), has supported research across the full range of science and medicine, with an underlying goal of enhancing the health, care, and well-being of military Service Members, Veterans, retirees, and their family members.

FY2023 Funding Mechanisms have been announced! The Congressionally Directed Topic Areas include:

Clinical Trial Award (CTA)
Discovery Award (DA)
Focused Program Award (FPA)
Investigator-Initiated Research Award (IIRA)
Lifestyle and Behavioral Health Interventions Research Award (LBIRA)
Technology/Therapeutic Development Award (TTDA)

Letter of Intent is Due: April 19th, 2023

Full Applications are Due: May 31st, 2023

Learn more about this opportunity at https://cdmrp.health.mil/funding/prmrp

Tags

Lockdown Auth

Notice of Special Interest (NOSI): Halting Tuberculosis (TB) Transmission

staatsc — Tue, 27 Sep 2022 14:40:05 +0000

Notice of Special Interest (NOSI): Halting Tuberculosis (TB) Transmission staatsc Tue, 09/27/2022 - 09:40 RSS:

Open Date (Earliest Submission Date): February 05, 2023

Expiration Date: January 08, 2026

The purpose of this Notice of Special Interest (NOSI) is to highlight NIAID’s interest in accepting applications that aim to understand the critical drivers of Tuberculosis (TB) transmission at the individual and population levels in high-burden settings. Applicants are encouraged to develop effective methods to measure rates of TB transmission that rely on an increased understanding of the biomedical basis of transmission and related risk factors and to develop and assess potential interventions, including low-cost and low-tech options, to prevent TB transmission.

For more information click here

Tags

TB, NIH, NIAID

Lockdown Auth

Contract Solicitation: Mycobacterium tuberculosis (MTB) Quality Assessment Program (TBQA)

staatsc — Wed, 07 Sep 2022 16:16:33 +0000

Contract Solicitation: Mycobacterium tuberculosis (MTB) Quality Assessment Program (TBQA) staatsc Wed, 09/07/2022 - 11:16 RSS:

The purpose of the proposed contract will be to provide a Mycobacterium tuberculosis (MTB) Quality Assessment Program (TBQA), a resource to: (1) support the ability of laboratories (Labs) to reliably perform study-specified MTB tests; (2) evaluate MTB technologies and specimen processes for use in clinical investigations; and (3) disseminate technical and scientific data.

Notice ID: 75N93022R00015

Original Published Date: Aug 31, 2022 08:19 am EDT
Original Date Offers Due: Nov 30, 2022 03:00 pm EST

For more info, click here

Lockdown Auth

Catalyst Award for Early-Stage Investigators (ESIs) Pursuing Research on HIV Comorbidities, Coinfections, and Complications (DP1- Clinical Trial Optional)

staatsc — Mon, 29 Aug 2022 18:49:22 +0000

Catalyst Award for Early-Stage Investigators (ESIs) Pursuing Research on HIV Comorbidities, Coinfections, and Complications (DP1- Clinical Trial Optional) staatsc Mon, 08/29/2022 - 13:49 RSS:

Open Date (Earliest Submission Date): April 01, 2023

Expiration Date: May 02, 2025

This funding opportunity announcement (FOA) supports research from creative early stage investigators who propose highly innovative, pioneering studies with potential to open new areas of HIV/AIDS research related to coinfections, comorbidities, and complications. Projects should reflect new and novel scientific directions that are distinct from concepts and approaches being pursued in the investigator’s research program or elsewhere. Projects must be consistent with the scientific priorities outlined by the NIH Office of AIDS Research (OAR). These priorities have been described most recently in NOT-OD-20-018.

For more information click here

Lockdown Auth

Identifying Host Cell Death Pathway Targets for Host-Directed Therapies for Treatment of Mtb and Mtb/HIV Co-Infection (R01, Clinical Trial Not Allowed)

staatsc — Wed, 17 Aug 2022 19:17:21 +0000

Identifying Host Cell Death Pathway Targets for Host-Directed Therapies for Treatment of Mtb and Mtb/HIV Co-Infection (R01, Clinical Trial Not Allowed) staatsc Wed, 08/17/2022 - 14:17 RSS:

Open Date (Earliest Submission Date): November 07, 2022

Expiration Date: December 08, 2024

The purpose of this Funding Opportunity Announcement (FOA) is to support mechanistic studies on host cell death pathways and their effect on immune responses to Mycobacterium tuberculosis (Mtb) and Mtb/HIV co-infection to identify immune targets for development of host-directed therapies.

For more information click here

Lockdown Auth

TB Centers of Excellence - Grants Notice

staatsc — Mon, 11 Jul 2022 15:02:20 +0000

TB Centers of Excellence - Grants Notice staatsc Mon, 07/11/2022 - 10:02 RSS:

TB Centers of Excellence for Training, Education and Medical Consultation (COE)

CDC plans to establish and fund up to four regionally-assigned Tuberculosis Centers of Excellence (TB COE) to facilitate efforts to prevent, treat, and control TB disease and latent TB infection (LTBI) in the United States (U.S.). The TB COE will focus on two major activities: (1) increasing knowledge, skills, and abilities for TB prevention and control through communication, education, and training activities, and; (2) improving sustainable evidence based TB clinical practices and patient care through the provision of expert medical consultation. The funds available for these core activities will be used to support TB and LTBI communication efforts, training, education, and medical consultation activities.

Funding Organization

Centers for Disease Control and Prevention - NCHHSTP

Closing Date for Applications

September 6th, 2022

For more information, https://www.grants.gov/web/grants/view-opportunity.html?oppId=336618

Lockdown Auth

TB Elimination Alliance Announces 2022-2023 Mini-Grant Program

staatsc — Fri, 08 Jul 2022 13:57:45 +0000

TB Elimination Alliance Announces 2022-2023 Mini-Grant Program staatsc Fri, 07/08/2022 - 08:57 RSS:

The Tuberculosis (TB) Elimination Alliance (TEA) is offering Mini-Grants to organizations serving Asian American (AA), Native Hawaiian, and Pacific Islander (NH/PI) communities that are disproportionately impacted by latent TB infection (LTBI) and/or TB. Additional preference is given to organizations currently serving Asian/Asian American (A/AA) and NH/PI populations with an interest in expanding to non-US born Latino American, and US born African American communities.

Mini-Grant proposals must align with TEA’s priority areas and activities that reflect community engagement and education, provider education, and/or quality improvement.

Up to 15 awards will be provided to selected organizations. Each award amount will be between $10,000 and $30,000. Deadline to apply is Friday, August 5 by 5:00pm local time.

For more information please visit, https://tbeliminationalliance.org/2022-2023-tb-elimination-alliance-mini-grant-program-request-for-funding-proposal/

Lockdown Auth

NIAID June 2022 Council-Approved Concepts

staatsc — Tue, 28 Jun 2022 18:15:27 +0000

NIAID June 2022 Council-Approved Concepts staatsc Tue, 06/28/2022 - 13:15 RSS:

Concepts represent early planning stages for program announcements, requests for applications, notices of special interest, or solicitations for Council's input. Concepts reveal possible initiatives or give you ideas for an investigator-initiated application.

Analyzing Early Events in Tuberculosis (TB) and TB/HIV Infection To Identify Interventional Targets

Request for Applications—proposed FY 2024 initiative

Objective: Early events associated with Mycobacterium tuberculosis (Mtb) infection are not well understood. However, studies delineating the initial stage of Mtb infection may identify unique targets for more effective vaccine adjuvants and immunomodulators, as well as improved biomarkers to advance prevention and therapy of TB. The objectives of this initiative are to better understand how Mtb evades and disrupts host immunity at the earliest stages of infection, and how myeloid (macrophages, dendritic cells, eosinophils), lymphoid (T cells, B cells, innate lymphoid cells) and non-immune cells (alveolar epithelial cells, pneumocytes, vascular) in the airway and lung interact with Mtb and each other. Furthermore, delineating the effects of HIV co-infection on immune mechanisms during early Mtb infection will facilitate the development of effective immune-based interventions for people living with HIV.

Contact:
Robert Mahon
robert.mahon@nih.gov

Consortium for Design of TB Drug Regimens

Request for Applications—proposed FY 2024 initiative

Objective: To establish a consortium of tuberculosis (TB) preclinical and clinical experts to systematically refine preclinical models with clinical data and identify the most efficacious combination regimens for future clinical testing to optimize relapse-free TB treatment.

Contact:
Barbara Laughon
blaughon@mail.nih.gov

Mycobacterium tuberculosis Quality Assessment (TBQA) Program

Request for Proposals—proposed FY 2024 initiative

Objective: TBQA will 1) support the ability of laboratories to reliably perform study-specified Mycobacterium tuberculosis (Mtb) tests; 2) evaluate Mtb technologies and specimen processes for use in clinical investigations; 3) disseminate technical and scientific data; 4) perform late-stage assay validation and/or Mtb assay testing of clinical samples in a CLIA-certified laboratory (Option); and 5) support public health emergency needs (Option). The TBQA will serve NIAID-sponsored and collaborating clinical trial networks and cohorts as well as individual grantees conducting research in and outside the United States. Examples of NIAID-sponsored Networks include the Adult AIDS Clinical Trials Group (ACTG), the International Maternal Pediatric and Adolescent AIDS Clinical Trials Group (IMPAACT), and the HIV Vaccine Trials Network (HVTN). Examples of NIAID-sponsored TB cohorts include the India and Brazil Regional Prospective Observational Research for Tuberculosis (RePORT).

Contact:
Isaac Elliott
isaac.elliott@nih.gov

You can find more information here

Tags

NIH

Lockdown Auth

Sustained Release of Antivirals for Treatment or Prevention of HIV or Treatment of Latent TB/HBV (SRATP), due September 07, 2022

staatsc — Fri, 17 Jun 2022 17:45:13 +0000

Sustained Release of Antivirals for Treatment or Prevention of HIV or Treatment of Latent TB/HBV (SRATP), due September 07, 2022 staatsc Fri, 06/17/2022 - 12:45 RSS:

Open Date (Earliest Submission Date): September 07, 2022

Expiration Date: May 08, 2025

The purpose of this Notice is to encourage new applications to support further development of a diverse and comprehensive portfolio of SR/LA products for prevention and treatment of HIV. SR/LA antiretroviral products will have a minimum window of protection of three (3) months from either a single dosing (injection, oral administration) or continuous dosing regimen (implant, transdermal patch, etc.) to reflect current state of SR/LA drug market for HIV treatment or prevention.

This Notice also encourages applications to develop once-a-month SR/LA strategies for treatment of latent TB and hepatitis B

https://grants.nih.gov/grants/guide/notice-files/NOT-AI-22-042.html?utm…

Tags

NIAID, TB, LTBI, HIV

Lockdown Auth

January 2022 DAIDS Council-Approved Concepts

vanselhj — Fri, 18 Mar 2022 22:33:12 +0000

January 2022 DAIDS Council-Approved Concepts vanselhj Fri, 03/18/2022 - 17:33 RSS:

Notice of Special Interest (NOSI)—Identifying Immune Cell Death Pathway Targets for Host-Directed Therapies for Treatment of Mtb and Mtb/HIV Co-Infection

Notice of Special Interest—proposed FY 2023 initiative

Contact:
Josh Radke
josh.radke@nih.gov

Objective: NIAID has a specific interest in research toward understanding the role cell death mechanisms (CDMs) play in response to Mycobacterium tuberculosis (Mtb) infection, how Mtb subverts cell death pathways to promote infection, and to identify cellular targets that could be exploited as potential host-directed therapies to treat Mtb and Mtb/HIV co-infection.

https://www.niaid.nih.gov/grants-contracts/january-2022-daids-council-approved-concepts#05

Lockdown Auth

Biomarker Signatures of TB Infection in Young Children With and Without HIV (R01 Clinical Trial Not Allowed), due 06/08/2022

vanselhj — Wed, 09 Mar 2022 18:13:42 +0000

Biomarker Signatures of TB Infection in Young Children With and Without HIV (R01 Clinical Trial Not Allowed), due 06/08/2022 vanselhj Wed, 03/09/2022 - 12:13 RSS:

Open Date (Earliest Submission Date): May 08, 2022

Expiration Date: June 09, 2022

The purpose of this Funding Opportunity Announcement (FOA) is to advance research to discover and validate novel biomarkers of Tuberculosis (TB) infection and subsequent risk of progression to TB disease in young children with and without HIV.

https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-22-015.html

Tags

TB, HIV, Pediatrics, NIAID

Lockdown Auth

Improved Drug Susceptibility Testing (DST) for Tuberculosis (R01 Clinical Trial Not Allowed), due 07/08/2022

vanselhj — Wed, 09 Mar 2022 18:01:53 +0000

Improved Drug Susceptibility Testing (DST) for Tuberculosis (R01 Clinical Trial Not Allowed), due 07/08/2022 vanselhj Wed, 03/09/2022 - 12:01 RSS:

Open Date (Earliest Submission Date): June 08, 2022

Expiration Date: July 09, 2022

The purpose of this Funding Opportunity Announcement (FOA) is to support the development of new diagnostic technologies for tuberculosis (TB) drug susceptibility testing (DST), including point of care (POC) DST and companion diagnostics for new TB drugs.

https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-22-016.html

Tags

TB, NIAID

Lockdown Auth

Contract Solicitation - 2022 NIAID Omnibus Broad Agency Announcement

linharlc — Thu, 20 Jan 2022 21:45:58 +0000

Contract Solicitation - 2022 NIAID Omnibus Broad Agency Announcement linharlc Thu, 01/20/2022 - 15:45 RSS:

NIAID 2022 OMNIBUS BROAD AGENCY ANNOUNCEMENT (BAA) NO. HHS-NIH-NIAID-BAA2022-1 contains four (4) distinct Research Areas, each with specified closing date and time. The proposal due date of March 18, 2022, specified in this solicitation posting, is the due date for Research Area 003 only. An Amendment will be issued at a later date to update the proposal due date for responses to Research Areas 001, 002, 004. The proposal due dates for each Research Area are identified below:

Research Area 001 - Development of Vaccine Candidates for Biodefense, Antimicrobial Resistant (AMR) Infections and Emerging Infectious Diseases

Proposals Due Date and Time - 3:00 PM Eastern Time on April 18, 2022

Research Area 002 - Development of Therapeutic Candidates for Biodefense, Antimicrobial Resistant (AMR) Infections and Emerging Infectious Diseases

Proposals Due Date and Time - 3:00 PM Eastern Time on April 18, 2022

Research Area 003 - The Antiviral Program for Pandemics (APP): Development of Antivirals for Specific RNA Viral Families of Pandemic Potential

Proposals Due Date and Time - 3:00 PM Eastern Time on March 18, 2022

Research Area 004 - Development of In Vitro Diagnostics for Biodefense, Antimicrobial Resistant Infections (AMR), and Emerging Infectious Diseases

Proposals Due Date and Time - 3:00 PM Eastern Time on April 18, 2022

For more information click HERE!!

Tags

NIH

Lockdown Auth

September 2021 NIAID Council-Approved Concepts

linharlc — Thu, 28 Oct 2021 18:41:22 +0000

September 2021 NIAID Council-Approved Concepts linharlc Thu, 10/28/2021 - 13:41 RSS:

Improved Drug Susceptibility Testing (DST) for Tuberculosis!

Request for Applications—proposed FY 2023 initiative

Objective: To support the development of new diagnostic technologies for tuberculosis (TB) drug susceptibility testing (DST), including point-of-care DST and companion diagnostics for new TB drugs.

Description: This concept would further the development of new diagnostic technologies for TB DST with an emphasis on rapid, point-of-care, low complexity assays. As new drugs move forward in the pipeline, there is a need for companion DST diagnostics for new drugs to ensure new drugs are used most effectively. Current phenotypic methods for determining drug resistance (DR) provide clinically relevant drug susceptibility information but have limitations. For example, the gold standard relies on culture, requires time for growth, and does not provide a result for many days. The program would solicit highly innovative DST assays, including phenotypic DST that may rely on a readout that does not require full growth as in traditional DST assays. Innovative technologies beyond nucleic acid amplification tests will be encouraged. This effort is anticipated to include exploratory work that would further improve our knowledge of genotypic and phenotypic correlates of clinical DR, which can be complex. Research that leverages the rapid advances in diagnostic technologies for COVID-19 applied to TB are also encouraged. Furthermore, this effort would be targeted to technology holders partnered with academic, clinical, and laboratory colleagues with TB diagnostic expertise.

Contact: Karen Lacourciere

lacourcierek@niaid.nih.gov

240-627-3297

Click here for more information!

Lockdown Auth

NIAID Funding Opportunity: Brazil Regional Prospective Observational Research in Tuberculosis

linharlc — Fri, 06 Aug 2021 21:49:03 +0000

NIAID Funding Opportunity: Brazil Regional Prospective Observational Research in Tuberculosis linharlc Fri, 08/06/2021 - 16:49 RSS:

Brazil Regional Prospective Observational Research in Tuberculosis (RePORT) (U01 Clinical Trial Not Allowed)

Application open date: November 08, 2021

Expiration Date: December 09, 2021

The purpose of this Funding Opportunity Announcement (FOA) is to support a Brazil-US Regional Prospective Observational Research in Tuberculosis (RePORT) network to advance TB and TB/HIV science. The RePORT Brazil network will leverage and build upon Brazilian cohorts currently following adult and pediatric populations with active TB disease and their contacts or other high TB-risk individuals to address key research questions of regional and global interest. Specific areas supported under this program include, but are not limited to, research and development projects in TB/HIV in the areas of molecular epidemiology, diagnostics, biomarkers, vaccine development, and the impact of co-morbidities such as HIV and diabetes. Research outcomes should be capable of advancing tools with public health impact or of influencing decision making in TB public health to inform stakeholders on the best practices for early prevention, diagnosis, and clinical management of TB and TB/HIV.

Click here for more information about this funding opportunity!

Tags

TB, RePORT-Brazil

Lockdown Auth

June 2021 DAIDS Council-Approved Concepts

linharlc — Wed, 14 Jul 2021 14:43:32 +0000

June 2021 DAIDS Council-Approved Concepts linharlc Wed, 07/14/2021 - 09:43 RSS:

FY 2022 Concepts

Brazil Regional Prospective Observational Research in Tuberculosis (RePORT)

Objective: The primary objective of this initiative is to enable a network of Brazilian and U.S. scientists to advance current understanding of the community, host, and microbial factors that impact outcomes of tuberculosis (TB) infection and TB disease, especially among persons with HIV (PWH), including drug-resistant (DR)-TB, to facilitate developing tools to improve treatment outcomes at the individual level and inform strategies to curtail the TB epidemic at the public health level.

To achieve this, the initiative will support a Brazil-U.S. Regional Prospective Observational Research in Tuberculosis (RePORT) network that will leverage the robust clinical research infrastructure that exists within Brazil to capacitate a wide range of research.

Contact: Dr Sudha Srinivasan

FY 2023 Concepts

South Africa Regional Prospective Observational Research in Tuberculosis (RePORT)

Objective: The primary objective of this initiative is to enable a network of South African and U.S. scientists to advance current understanding of the community, host, and microbial factors that impact outcomes of tuberculosis (TB) infection and TB disease, especially among persons with HIV (PWH), including drug-resistant TB, to facilitate development of tools to improve treatment outcomes at the individual level and to inform strategies to curtail the TB epidemic at the public health level.

To achieve this, the initiative will support a South Africa-U.S. Regional Prospective Observational Research in Tuberculosis (RePORT) network that will leverage the robust clinical research infrastructure that exists within South Africa to capacitate this research.

Contact: Dr Sudha Srinivasan

RePORT International Coordinating Center (RICC)

Objective: The primary objective of this initiative is to advance tuberculosis (TB) and TB/HIV research by supporting coordination of global research efforts undertaken by the various in-country Regional Prospective Observational Research for Tuberculosis (RePORT) networks and other research partners. The RePORT International Coordinating Center (RICC) enables coordination and acceleration of research across the six RePORT countries (India, Brazil, South Africa, China, Indonesia, and Philippines) and fosters a synergistic approach. This will allow for maximizing resources, validating research findings, and generating globally applicable research outcomes in a timely manner.

Contact: Dr Sudha Srinivasan

Biomarker Signatures of Tuberculosis Infection in Young Children With and Without HIV

Objective: The goal of this initiative is to advance research to discover and validate novel biomarkers of tuberculosis (TB) infection and subsequent risk of progression to TB disease in young children with and without HIV.

Contact: Patrick Jean-Philippe

Click here for more information!

Lockdown Auth

Advancing Vaccine Adjuvant Research for Tuberculosis (TB)

linharlc — Mon, 03 May 2021 16:34:38 +0000

Advancing Vaccine Adjuvant Research for Tuberculosis (TB) linharlc Mon, 05/03/2021 - 11:34 RSS:

Solicitation for BAA-DAIT-75N93021R00008 entitled, "Advancing Vaccine Adjuvant Research for Tuberculosis (TB)"

Contract Opportunity Type: Solicitation

The goal of this program is to further the development of TB vaccines through sideby-side comparisons of adjuvants in combination with TB immunogens, and to establish immunological profiles of adjuvants that work through different mechanisms, facilitating the identification of the most promising adjuvant:Mtb immunogen candidates for clinical development and potential immune correlates of protection. The range of adjuvants to be evaluated may include novel classes of adjuvants being developed for other infections and immune-oncology therapeutics, as well as adjuvants already being developed for TB vaccines. It is anticipated that one cost reimbursement, completion type contract will be awarded for a five [5]-year period of performance beginning on or about 7/22/22.
NIAID anticipates that the average annual total cost (direct and indirect costs combined) is $4 million per contract. However, it is anticipated that the total cost for the award(s) may vary depending upon the scope of the project and the technical objectives of the award(s). The length of time for which funding is requested should be consistent with the nature and complexity of the proposed research. In no event shall the period of performance proposed by an offeror exceed five [5] years. Any responsible offeror may submit a proposal which shall be considered by the Agency. This BAA will be available electronically on/about April, 28, 2021, and may be accessed through here. This notice does not commit the Government to award a contract. No collect calls will be accepted. No facsimile transmissions will be accepted.

Published: Apr 28, 2021 12:41 pm EDT
Offers Due: Aug 10, 2021 03:00 pm EDT

Tags

NIH, TB, NIAID

Lockdown Auth

Postdoctoral Fellowship opportunity in Global HIV & TB Research

linharlc — Mon, 26 Apr 2021 15:02:17 +0000

Postdoctoral Fellowship opportunity in Global HIV & TB Research linharlc Mon, 04/26/2021 - 10:02 RSS:

Post-Doctoral Research Fellowships for Global HIV and TB Public Health Programs

The mission of this fellowship program is to recruit, mentor, and train scientist-practitioners to conduct global HIV and TB research and to develop the translational and applied skills necessary to implement and support high-quality HIV and TB public health programs in global settings. The goal of this fellowship is to attract and support recent recipients of doctoral degrees to understand the underpinnings of interventional epidemiology and to prepare them for a career operating at the intersection of science and practice in global public health. The selected candidates will be in the Division of Global HIV & TB (DGHT) at the Centers for Disease Control and Prevention (CDC), headquartered in Atlanta, GA. The DGHT Office of the Director (DGHT OD) is the lead for the program. Fellows will also be paired with DGHT’s programmatic or data branches on various projects throughout their fellowship.

The deadline to apply to this fellowship is June 30, 2021. The fellowship is scheduled to begin Fall 2021, subject to availability of funds.

Click here for more information about this fellowship!

Tags

CDC, TB, HIV

Lockdown Auth

Innovation for Tuberculosis Vaccine Discovery (ITVD) (R61/R33 Clinical Trial Not Allowed)

linharlc — Wed, 24 Feb 2021 15:04:40 +0000

Innovation for Tuberculosis Vaccine Discovery (ITVD) (R61/R33 Clinical Trial Not Allowed) linharlc Wed, 02/24/2021 - 09:04 RSS:

Application Due Date: June 30, 2021. Letter of Intent Due Date: 30 days prior to the application due date. Expires: July 01, 2021.

The purpose of this funding opportunity is to support the design of novel tuberculosis (TB) vaccine candidates that exploit innovative approaches and their advancement into preclinical animal model testing. This funding opportunity will use a milestone driven, biphasic award mechanism to fund high risk/exploratory research. Transition to the second phase depends on the successful completion of milestones.

https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-007.html?utm_campaign=+46333793&utm_content=&utm_medium=email&utm_source=govdelivery&utm_term=

Tags

NIH, NIAID

Lockdown Auth